Most patients had grade 3 (10/19, 53%) ductal carcinoma (15/19, 79%), estrogen receptor-positive (12/19, 63%), progesterone receptor positive (12/19, 63%), and human epidermal growth factor receptor 2 (HER-2) negative (15/19, 79%). This evidence concerns the gene PGR and breast ductal adenocarcinoma.